Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro to join the Nordic Health Summit Japan 2025
2025-06-13
Salipro Biotech will join the Nordic Health Summit Japan 2025, taking place in Tokyo on June 27 (virtual)!
Lorena Galán and Peter Jahnmatz will be online to connect and discuss the advantages of the Salipro® technology with pharma leaders and innovators in Japan.
Book a meeting with us via the partnering platform to learn more about the latest advancements of Salipro® and explore collaboration opportunities in drug discovery targeting membrane proteins.
We look forward to fruitful meetings and engaging with the Japanese pharma ecosystem!
Press Release: Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
2025-06-11
The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical’s drug discovery programs for the generation of small molecule drugs.
Seoul, Korea – June 11, 2025 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech’s expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong’s development of novel small molecule drugs.
Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target.
Salipro invited to speak at Discovery & Development Europe
2025-06-04
Our CEO, Jens Frauenfeld, will be a featured speaker at Discovery & Development Europe on June 24 at 1PM in Basel, Switzerland!
Jens will be sharing insights into how the Salipro® technology is unlocking drug discovery targeting complex membrane proteins. We will present how we're enabling advancements in small molecule discovery and characterization, particularly showcasing our latest progress in DEL-based hit identification using functional membrane proteins.
We look forward to discussing opportunities to collaborate and making new connections.
Let’s meet in Basel on June 23-24!
Find more information on the official conference website: https://oxfordglobal.com/discovery-development/events/discovery-development-europe